publication date: Mar. 6, 2020
NCI Trials
NCI Trials for March 2020
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
For further information, contact the principal investigator listed.
Phase I – 10317
A Pilot Study of Nivolumab in Combination with Decitabine and Venetoclax in TP53-Mutated Acute Myeloid Leukemia
Ohio State University Comprehensive Cancer Center LAO
Mims, Alice Scott
(614) 685-6031
Phase I – 10324
A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) with M3814 in Platinum – Resistant or Ineligible Ovarian and Related Cancers with Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)
JHU Sidney Kimmel Comprehensive Cancer Center LAO
Grisham, Rachel Nicole
(646) 888-4653
Phase I – FOR0003
A Phase I Trial of D2C7-IT in Combination with Atezolizumab in Recurrent WHO Grade IV Malignant Glioma
Duke University Medical Center
Randazzo, Dina Marie
(919) 613-3712
Phase II – ARST1921
A Safety, Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor, Nirogacestat (PF-03084014; IND# 146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors
Children’s Oncology Group
Navid, Fariba
(323) 361-5418
Phase II – S1900B
A Phase II Study of LOXO-292 in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
SWOG
Elamin, Yasir Y.
(713) 792-3428
Phase III – NRG-GU008
Randomized Phase III Trial … Continue reading NCI Trials for March 2020To access this members-only content, please log in.Institutional subscribers, please
log in with your IP.
If you're not a subscriber why not
join today? To gain access to the members only content
click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.
